NeuroAiD is a herbal supplement proposed to support functional recovery after strokes. [1] There were two formulations of NeuroAiD: MLC601 (NeuroAiDTM) was first developed. [1] Since 2018 MLC601 formulation is no longer on the market, and has been replaced by MLC901 (NeuroAiDTMII), a simplified formulation containing only 9 botanical ingredients. [2] It can be administered orally or through a feeding tube. [3]
The drug shows no significant benefit in improving outcomes at 3 months in patients with acute ischemic stroke. [4]
NeuroAiD was first registered and marketed in China in 2001. [1] [5] It is derived from traditional Chinese medicine. [5] [6] [7] According to the CEO of Moleac, NeuroAiD is sold in at least 25 countries, and 20,000 people have taken it. [8]
NeuroAiD I, or MLC601, is composed of nine herbal components ( astragalus root, Salvia miltiorrhiza root, chishao, rhizome lovage, Angelica sinensis root, safflower, peach, thinleaf milkwort root, and grassleaf sweet flag rhizome) and five components derived from animals ( Hirudo medicinalis, Eupolyphaga seu steleophaga, Calculus bovis artifactus, Buthus martensii, and Cornu saigae tataricae). [9] NeuroAiDTMII, or MLC901, is a simpler form of the medication that only contains the nine herbal components without the animal components. [2] Since 2018, MLC601 formulation is no longer marketed.
Laboratory studies suggest that NeuroAiD can aid with stroke recovery by improving neuroprotection, neurogenesis, and neuroplasticity by amplifying endogenous processes of self-protection and self-repair of the brain. [2] [10] [11] MLC901 can activate KATP channels, which has a neuroprotective effect against brain ischemia. [12]
Neuroaid was statistically no better than placebo in improving stroke recovery at 3 months post-stroke. [13]
Additionally, recent research indicates that NeuroAid improves cognitive functioning after traumatic brain injury [14] and could potentially play a role in treating severe traumatic spinal cord injuries, [15] as well as in slowing down the progression of Alzheimer's disease. [16]
Common side effects include abdominal discomfort, headaches, dry mouth, nausea, vomiting, and diarrhea. Frequently, they can be relieved by reducing the dosage of the medication by 50% for a week. Once the symptoms have resolved, the usual dosage can be resumed. [1] In some rare cases during clinical trials, a few patients experienced serious side effects (jaundice, low potassium levels, recurring strokes). [6]
The medication is contraindicated in pregnant and breastfeeding women. [17]
NeuroAiD was approved by the Sino Food and Drug Administration in August 2001, under the name Danqi Piantan Jiaonang. [9] [18] NeuroAiD has also been approved for use in other Asian countries such as Singapore. [19] In 2006, NeuroAiD was also chosen for the Chinese Ministry of Science and Technology's Key Technologies Research & Development program. [20]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
NeuroAiD is a herbal supplement proposed to support functional recovery after strokes. [1] There were two formulations of NeuroAiD: MLC601 (NeuroAiDTM) was first developed. [1] Since 2018 MLC601 formulation is no longer on the market, and has been replaced by MLC901 (NeuroAiDTMII), a simplified formulation containing only 9 botanical ingredients. [2] It can be administered orally or through a feeding tube. [3]
The drug shows no significant benefit in improving outcomes at 3 months in patients with acute ischemic stroke. [4]
NeuroAiD was first registered and marketed in China in 2001. [1] [5] It is derived from traditional Chinese medicine. [5] [6] [7] According to the CEO of Moleac, NeuroAiD is sold in at least 25 countries, and 20,000 people have taken it. [8]
NeuroAiD I, or MLC601, is composed of nine herbal components ( astragalus root, Salvia miltiorrhiza root, chishao, rhizome lovage, Angelica sinensis root, safflower, peach, thinleaf milkwort root, and grassleaf sweet flag rhizome) and five components derived from animals ( Hirudo medicinalis, Eupolyphaga seu steleophaga, Calculus bovis artifactus, Buthus martensii, and Cornu saigae tataricae). [9] NeuroAiDTMII, or MLC901, is a simpler form of the medication that only contains the nine herbal components without the animal components. [2] Since 2018, MLC601 formulation is no longer marketed.
Laboratory studies suggest that NeuroAiD can aid with stroke recovery by improving neuroprotection, neurogenesis, and neuroplasticity by amplifying endogenous processes of self-protection and self-repair of the brain. [2] [10] [11] MLC901 can activate KATP channels, which has a neuroprotective effect against brain ischemia. [12]
Neuroaid was statistically no better than placebo in improving stroke recovery at 3 months post-stroke. [13]
Additionally, recent research indicates that NeuroAid improves cognitive functioning after traumatic brain injury [14] and could potentially play a role in treating severe traumatic spinal cord injuries, [15] as well as in slowing down the progression of Alzheimer's disease. [16]
Common side effects include abdominal discomfort, headaches, dry mouth, nausea, vomiting, and diarrhea. Frequently, they can be relieved by reducing the dosage of the medication by 50% for a week. Once the symptoms have resolved, the usual dosage can be resumed. [1] In some rare cases during clinical trials, a few patients experienced serious side effects (jaundice, low potassium levels, recurring strokes). [6]
The medication is contraindicated in pregnant and breastfeeding women. [17]
NeuroAiD was approved by the Sino Food and Drug Administration in August 2001, under the name Danqi Piantan Jiaonang. [9] [18] NeuroAiD has also been approved for use in other Asian countries such as Singapore. [19] In 2006, NeuroAiD was also chosen for the Chinese Ministry of Science and Technology's Key Technologies Research & Development program. [20]
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)